“Cost-Effectiveness of Empagliflozin, in Addition to Metformin, in Patients With Type 2 Diabetes in Italy”. 2022. Farmeconomia. Health Economics and Therapeutic Pathways 23 (1). https://doi.org/10.7175/fe.v23i1.1539.